Study: Triple-Hormone-Receptor Agonist Retatrutide for Obesity Journal: New England Journal of Medicine (NEJM) ClinicalTrials ID: NCT04881760 View Full Study Retatrutide is a glucagon, GLP-1, and GIP (triple hormone) receptor agonist being investigated to treat obesity
GLP-1 has a variety of physiological functions, which can regulate blood glucose level by promoting insulin secretion and synthesis, stimulating -cell proliferation and inducing islet regeneration, inhibiting -cell apoptosis and glucagon release, delaying gastric emptying and controlling appetite (Mller et al., 2019
Normal gut microbiota is subdivided into obligate (about 90%), facultative (9.5%), and transient (0.5%) populations (Smolinska et al., 2017)
This threat counts for infertility prevalence of 15% amongst the couples where 50% is solely male infertility [1]
The purpose of this review is to comprehensively investigate of the emerging understanding of the pleiotropic role of the carnitine pool, carnitine/acylcarnitines are not only auxiliaries or metabolites of fatty acid oxidation, but also play more complex and diverse roles, including energy metabolism, mitochondrial homeostasis, epigenetic regulation, regulation of inflammation and the immune system, tumor biology, signal transduction, and neuroprotection
